Intravenous immunoglobulin (IVIG), a pooled normal IgG from several thousand healthy donors and one of the commonly used immunotherapeutic molecules for the management of autoimmune and inflammatory diseases, has been explored for the treatment of coronavirus disease‐19 (COVID‐19). Although placebo‐controlled, double‐blind randomised clinical trials are lacking, current data from either retrospective, case series or open‐label randomised controlled trials provide an indicator that IVIG immunotherapy could benefit severe and critically ill COVID‐19 patients. See alsoShao et al.

中文翻译：

---

冠状病毒病19（COVID-19）的静脉免疫球蛋白免疫疗法

静脉内免疫球蛋白（IVIG）是几千名健康供体的汇集的正常IgG，并且是用于治疗自身免疫和炎性疾病的常用免疫治疗分子之一，已被用于治疗冠状病毒19型（COVID-19）。尽管尚缺乏安慰剂对照，双盲随机临床试验，但回顾性，病例系列或开放标签随机对照试验的最新数据提供了一个指标，表明IVIG免疫疗法可以使重症和重症COVID-19患者受益。另见Shao等。